论文部分内容阅读
自20世纪50年代初发现第一个多烯大环内酯抗生素以来,已报道了100多种此类抗生素,并且每年都在不断地发现。只有早期分离的那些化合物用于人体化疗,然而没有一种在临床试验中显示出优越性。其主要原因是,多烯大环内酯抗生素对人体显示很强的毒性,虽然它们对大多数真菌和酵母有很强的抑制活力。在筛选细菌合成的非多烯大环内酯的新的抗真菌药物时,排除多烯大环内酯抗生素是很有必要的。多烯大环内酯抗生素是由放线菌,特别是链霉素产生的,已报道有34%到88%的此类菌产生多烯大环内
Since the discovery of the first polyene macrolide antibiotic in the early 1950s, more than 100 such antibiotics have been reported and are constantly being discovered annually. Only those compounds that were initially isolated were used for human chemotherapy, but none showed the superiority in clinical trials. The main reason is that polyene macrolide antibiotics show strong toxicity to the human body, although they have a strong inhibitory activity on most fungi and yeasts. In the screening of novel non-polyene macrolide bacterial synthesis of new anti-fungal drugs, excluding polyene macrolide antibiotics is necessary. Polyene macrolide antibiotics are produced by actinomycetes, particularly streptomycin, and 34% to 88% of such bacteria have been reported to produce polyene macrocycles